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HOSPITAL GRAND ROUNDS
UKC Maribor, by Editorial Board Member Radovan Hojs
University Medical Centre (UKC) Maribor, Slovenia, provides secondary and tertiary healthcare services to patients from Maribor and 
northeastern part of Slovenia. It has status of teaching hospital and it is learning base for medical students. The origin of UKC Maribor 
reaches back to the Maribor city hospital that has been treating patients since 14th century and constantly developing since its official 
establishment in 1799. Today UKC Maribor employs 3400 staff members, of them approx. 600 medical doctors.
Part of UKC Maribor is Clinic for Internal medicine that includes departments of Cardiology and Angiology, Gastroenterology, Endocrinology 
and Diabetology, Nephrology, Dialysis, Rheumatology, Haematology and Hematologic Oncology, Pulmonary Diseases, Nuclear Medicine, 
Internal Intensive Medicine and Emergency Medical Unit.
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ABSTRACT
Amiodarone is an antiarrhythmic drug, in use from the 1960s, which acts on potassium transport in myocytes, causing a lengthening of 
the action potential and refractory period. Even though it is broadly prescribed, its use is limited by a relatively high occurrence of adverse 
reactions such as lung, thyroid or hepatic disease, skin changes and so on. The authors report a case of a female patient who was admitted 
due to chest pain. Due to the bluish skin pigmentation, other causes of amiodarone toxicity were investigated, and hyperthyroidism was 
detected. After amiodarone discontinuation and specific therapy, thyroid function returned to normal.
LEARNING POINTS
• Blue pigmentation of facial skin is an uncommon adverse effect of chronic amiodarone therapy that occurs in less than 3% of patients.
• When a patient is on chronic amiodarone therapy, signs of toxicity, such as hyperthyroidism, lung injury or hepatic disease, should be 
investigated.
• Regular liver and thyroid function tests and chest x-rays should be carried out on follow-up after initiation of amiodarone.
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INTRODUCTION 
Amiodarone is a commonly used antiarrhythmic drug, mostly for treatment of ventricular arrhythmias and symptomatic atrial fibrillation[1]. 
It has a high iodine content (37% by weight) and acts pharmacologically to inhibit the monodeiodination of thyroxine (T4), which often 
results in changes in thyroid function tests[2]. Furthermore, it is associated with thyroid dysfunction that can present itself as amiodarone-
induced hypothyroidism (AIH), present in approximately 5% of amiodarone-treated patients, or thyrotoxicosis (AIT), present in 7–15% 
of amiodarone-treated patients[2,3]. AIT can be further classified into type 1, type 2 or mixed type. Type 1 is a form of iodine-induced 
hyperthyroidism that usually develops in nodular goitre or latent Graves’ disease, type 2 is a destructive thyroiditis occurring in an otherwise 
healthy thyroid, while a mixed/indefinite type presents an overlapping condition[2].
The use of amiodarone is limited by its toxicity presenting as hepatic, gastrointestinal, pulmonary, thyroid, neurologic, dermatologic, 
ophthalmologic, haematologic, psychiatric or cardiac adverse effects[4]. Although uncommon, bluish skin pigmentation is present in 1–7% of 
patients on chronic amiodarone therapy, while photosensitivity appears in 24–57%. This is thought to be due to lipofuscin accumulation in 
lysosomes in sun-exposed areas due to phototoxic damage or drug deposition within dermal cells. Other adverse effects due to amiodarone 
have no known association to bluish skin discoloration[4,5]. Bluish skin discoloration has also been described in several conditions such 
as argyria, methaemoglobinaemia and ochronosis, and has been associated with several medications such as amiodarone, minocycline, 
chlorpromazine, chloroquine and hydroxychloroquine[6].  
CASE DESCRIPTION 
An 84-year-old female was admitted to the Internal Clinic for further work-up of a possible non-ST elevation myocardial infarction (NSTEMI). 
She had previously known chronic atrial fibrillation, arterial hypertension, diabetes mellitus type 2, and aortic and mitral insufficiency. On 
the day of admission, she felt an intense, sharp pain in her back that radiated to the left side of her thorax. Additionally, she described 
the pressure on her chest as stenocardic, only mildly alleviated by analgesics. Her regular therapy consisted of atorvastatin, valsartan, 
hydrochlorothiazide and amiodarone.
At admission she was oriented, afebrile, her blood pressure was 180/65 mmHg, heart rate 63 beats/min, peripheral oxygen saturation (SpO
2
) 
99%. The only abnormal findings in the clinical examination were bluish skin pigmentation of the face (Fig. 1), which the admitting doctor 
suggested was due to amiodarone, a systolic murmur and irregular heartbeat.
The ECG showed left axis deviation, sinus rhythm with a ventricular frequency of 65 beats/min, ST depression in D1, aVL, V4–5, biphasic T 
waves in V2–5 and signs of left ventricular hypertrophy. The ECG changes were not present in the previous ECG carried out 6 months prior.
The initial laboratory investigation showed normocytic anaemia (haemoglobin 112 g/l), hypokalaemia (2.7 mmol/l) and low vitamin B12 
(125 pmol/l). Serial troponin measurements (5x) were negative. 
During the patient’s hospitalization, chest x-ray showed dilatation of mediastinal vasculature and echocardiography showed dilatation of 
the ascending aorta. Thoracic computed tomography angiography was carried out, which showed a dilatation of the ascending aorta and 
changes in the descending aorta that could represent multiple penetrating ulcers evolving into an intramural haematoma and dissection 
with possible rupture. Cardiac surgeons and intervention radiologists were consulted and suggested conservative therapy for chronic type 
B dissection.
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Figure 1. Bluish skin pigmentation of the face
Due to the bluish skin pigmentation and history of chronic amiodarone therapy, which the patient received for atrial fibrillation for 
approximately 8 years, according to the hospital medical record, thyroid function tests were performed. Initial thyroid function tests 
showed: thyroid-stimulating hormone (TSH) 0.369 mU/l (reference values 0.27–24.2 mU/l), free thyroxine (FT4) 28.81 pmol/l (reference 
values 12.0–22.0 pmol/l), free triiodothyronine (FT3) 2.65 pmol/l (reference values 3.1–6.8 pmol/l). A thyroid ultrasound showed normal 
thyroid size, somewhat inhomogeneous tissue and several nodules with cystic degeneration, the largest measuring 9 mm. Testing for thyroid 
antibodies (antithyroid peroxidase antibody, aTPO; thyroid-stimulating immunoglobulin, TSI; antithyroglobulin antibody, aTg) was negative. 
Amiodarone was discontinued and thiamazole 10 mg twice daily was prescribed for AIT. A thyroid function test check-up after 2 weeks 
showed: TSH 0.055 mU/l, FT4 30.97 pmol/l, FT3 2.24 pmol/l. Thiamazole was elevated to 10 mg 3 times daily, while sodium perchlorate 3 
× 15 drops for 3 weeks and methylprednisolone 24 mg were additionally prescribed. One month later, the follow-up thyroid function tests 
showed: TSH 1.15 mU/l, FT4 18.88 pmol/l, FT3 1.4 pmol/l. Thiamazole was lowered to 5 mg 3 times daily and methylprednisolone was 
tapered 8 mg per week until discontinuation. The last thyroid function test check-up 1.5 months later showed: TSH 14.73 mU/l, FT4 12.55 
pmol/l, FT3 3.06 pmol/l. Thiamazole was discontinued.
DISCUSSION
Patients that have photosensitivity or have developed bluish skin discolouration due to amiodarone treatment are advised to avoid 
sun exposure, use sun-protective clothing and apply sunscreen. Cases have shown resolution of discolouration typically 1 year after 
discontinuation of amiodarone[4].
In patients on chronic amiodarone therapy, regular follow-up is necessary. In addition to patient history and examination, baseline liver and 
thyroid function tests, chest x-ray, pulmonary function tests and electrocardiographic assessment should be conducted. Liver and thyroid 
function tests should be repeated every 6 months; chest x-ray every year[1].
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The European Thyroid Association (ETA) published new guidelines regarding amiodarone-associated thyroid dysfunction in 2018. For 
AIT they recommend emergency treatment, especially in elderly patients or if left ventricular dysfunction is present. Discontinuation of 
amiodarone therapy is dependent on the underlying arrhythmia and AIT type. For AIT type 1, antithyroid drugs should be used along with 
sodium perchlorate to accelerate control of hyperthyroidism. For AIT type 2, oral glucocorticoids are considered first-line therapy. For mixed 
type AIT, thionamides should be given initially with the addition of glucocorticoids with a poor response. The ideal timing for glucocorticoid 
therapy for mixed type AIT is still unknown[2]. For AIT type 1 patients who need on-going amiodarone therapy, thyroidectomy is recommended 
once AIT is under control[3]. Our patient was started on thiamazole with the addition of sodium perchlorate and methylprednisolone because 
of a lack of response. With combined therapy she became euthyroid.
